EUVIMEDEUVIMED entdecken
Crossref

Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis

Nicole Sander, Dora Stölzl, Melina Fonfara, Jan Hartmann iD, Inken Harder, Ina Suhrkamp iD, Ivone Jakaša, Ellen van den Bogaard, Ivonne van Vlijmen-Willems, Silke Szymczak, Elke Rodriguez iD, Sascha Gerdes und 1 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Nicole Sander und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-13, Water Loss, Insensible. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: European Federation of Pharmaceutical Industries and Associations, DFG Research Infrastructure NGS_CC, Next Generation Sequencing Competence Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin (IL)-13 is a key driver of inflammation and barrier dysfunction in atopic dermatitis (AD). While there is robust evidence that tralokinumab – a monoclonal antibody that neutralizes IL-13 – reduces inflammation and clinical disease activity, less is known about its effects on barrier function.

Objectives

To characterize the effects of tralokinumab treatment on skin barrier function.

Methods

Transepidermal water loss (TEWL), stratum corneum hydration (SCH), natural moisturizing factor content, histopathological characteristics, biomarker expression and microbiome composition were evaluated in lesional, nonlesional and sodium lauryl sulfate-irritated skin of 16 patients with AD over the course of 16 weeks of tralokinumab treatment.

Results

All clinical severity scores decreased significantly over time. At week 16, mean TEWL in target lesions decreased by 33% (P = 0.01) and SCH increased by 58% (P = 0.004), along with a histological reduction in spongiosis (P = 0.003), keratin 16 expression and epidermal thickness (P = 0.001). In parallel, there was a significant decrease in several barrier dysfunction-associated and proinflammatory proteins such as fibronectin (P = 0.006), CCL17/TARC (P = 0.03) and IL-8 (P = 0.01), with significant changes seen as early as week 8. Total bacterial load and Staphylococcus aureus abundance were significantly reduced from week 2.

Conclusions

Tralokinumab treatment improved skin physiology, epidermal pathology and dysbiosis, further highlighting the pleiotropic role of IL-13 in AD pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicInterleukin-13Water Loss, InsensibleHumansFemaleMaleAdultMiddle AgedAntibodies, MonoclonalSkinYoung AdultSignal TransductionMicrobiota

Substanzen

Interleukin-13tralokinumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Laboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.
  • Department of Dermatology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.
  • Institute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany.

ORCID-Profile: Jan Hartmann, Ina Suhrkamp, Elke Rodriguez

Förderung

  • European Federation of Pharmaceutical Industries and Associations
  • DFG Research Infrastructure NGS_CC
  • Next Generation Sequencing Competence Network

Zitieren

APA

Sander, N., Stölzl, D., Fonfara, M., Hartmann, J., Harder, I., Suhrkamp, I., Jakaša, I., van den Bogaard, E., van Vlijmen-Willems, I., Szymczak, S., Rodriguez, E., Gerdes, S., & Weidinger, S. (2024). Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae138

Vancouver

Sander N, Stölzl D, Fonfara M, Hartmann J, Harder I, Suhrkamp I, et al. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae138

BibTeX
@article{Sander2024,
  author = {Sander, Nicole and Stölzl, Dora and Fonfara, Melina and Hartmann, Jan and Harder, Inken and Suhrkamp, Ina and Jakaša, Ivone and van den Bogaard, Ellen and van Vlijmen-Willems, Ivonne and Szymczak, Silke and Rodriguez, Elke and Gerdes, Sascha and Weidinger, Stephan},
  title = {Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae138}
}
Kostenlos starten →